With one rival down, Novartis-partnered biotech scores $100M round to fund mid-stage trials of fibrosis drug

Amber Tong

When Pliant Therapeutics bagged its $62 million B round almost two years ago, CEO Bernard Coulie positioned its lead program in idiopathic pulmonary fibrosis …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With one rival down, Novartis-partnered biotech scores $100M round to fund mid-stage trials of fibrosis drug

Amber Tong

Sign up to read this article for free.

FDA inspectors discover trucks carrying torn-up records leaving Indian generics factory

Aligos’ trial for oral MASH treatment succeeds, but placebo group shows odd trend

Lasker Award goes to three scientists who pioneered research behind GLP-1 drugs

Roche outlines commercial manufacturing strategy for GLP-1/GIP assets

Exclusive: Flagship-backed Valo Health loses interim CEO ahead of key Phase 2 readout

Breaking down silos with a new quantitative approach to drug development

With one ri­val down, No­var­tis-part­nered biotech scores $100M round to fund mid-stage tri­als of fi­bro­sis drug

Amber Tong

Sign up to read this article for free.

FDA in­spec­tors dis­cov­er trucks car­ry­ing torn-up records leav­ing In­di­an gener­ics fac­to­ry

Ali­gos’ tri­al for oral MASH treat­ment suc­ceeds, but place­bo group shows odd trend

Lasker Award goes to three sci­en­tists who pi­o­neered re­search be­hind GLP-1 drugs

Roche out­lines com­mer­cial man­u­fac­tur­ing strat­e­gy for GLP-1/GIP as­sets

Ex­clu­sive: Flag­ship-backed Va­lo Health los­es in­ter­im CEO ahead of key Phase 2 read­out

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

With one rival down, Novartis-partnered biotech scores $100M round to fund mid-stage trials of fibrosis drug

FDA inspectors discover trucks carrying torn-up records leaving Indian generics factory

Aligos’ trial for oral MASH treatment succeeds, but placebo group shows odd trend

Lasker Award goes to three scientists who pioneered research behind GLP-1 drugs

Roche outlines commercial manufacturing strategy for GLP-1/GIP assets

Exclusive: Flagship-backed Valo Health loses interim CEO ahead of key Phase 2 readout

Breaking down silos with a new quantitative approach to drug development